Catalyst
Slingshot members are tracking this event:
Incyte Corporation's (INCY) JAKAFI (Ruxolitinib) in Atopic dermatitis - PDUFA date under priority review extended by three months to September 21, 2021
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| INCY | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 21, 2021
Occurred Source:
https://investor.incyte.com/press-releases/press-releases/2021/Incyte-Announces-U.S.-FDA-Approval-of-Opzelura-ruxolitinib-Cream-a-Topical-JAK-Inhibitor-for-the-Treatment-of-Atopic-Dermatitis-AD/default.aspx
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Jakafi, Ruxolitinib, Atopic Dermatitis
